Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
146 hedge funds and large institutions have $725M invested in Intercept Pharmaceuticals, Inc. in 2023 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 26 closing their positions.
87% more capital invested
Capital invested by funds: $387M → $725M (+$337M)
85% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 26
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
16% more funds holding
Funds holding: 126 → 146 (+20)
66% less call options, than puts
Call options by funds: $23.1M | Put options by funds: $68.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$27.2M |
| 2 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$24.9M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$22.6M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$18.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.7M |
| 2 |
CP
Caligan Partners
New York
|
-$14.6M |
| 3 |
Citigroup
New York
|
-$11.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$11.1M |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$10.7M |
ICPT Hedge Fund Activity: Q3 2023 in Review
146 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2023, worth a combined $725M — up 87% from $387M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ICPT positions and 26 closed out — a net gain of 22 holders — while 45 added to existing stakes and 36 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $27.2M. The largest seller was Vanguard Group, cutting an estimated $29.7M.
- 146 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2023, up from 126 in Q2 2023.
- Funds reported $725M of Intercept Pharmaceuticals, Inc. stock for Q3 2023, up 87% quarter-over-quarter.
- 48 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2023 and 26 closed out, a net change of +22 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2023 was Magnetar Financial, an estimated $27.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2023 was Vanguard Group, an estimated $29.7M sold.
Based on aggregated 13F filings for Q3 2023.